Literature DB >> 25634683

Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study.

V Goede1, K Fischer1, A Engelke1, R Schlag2, S Lepretre3, L F C Montero4, M Montillo5, C Fegan6, E Asikanius7, K Humphrey8, G Fingerle-Rowson7, M Hallek9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25634683     DOI： 10.1038/leu.2015.14

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

1.  Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells.

Authors:  Michaela Patz; Polina Isaeva; Nche Forcob; Bianka Müller; Lukas P Frenzel; Clemens-Martin Wendtner; Christian Klein; Pablo Umana; Michael Hallek; Günter Krause
Journal:  Br J Haematol       Date:  2010-12-13       Impact factor: 6.998

2.  Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.

Authors:  Jan A Burger; Michael J Keating; William G Wierda; Elena Hartmann; Julia Hoellenriegel; Nathalie Y Rosin; Iris de Weerdt; Ghayathri Jeyakumar; Alessandra Ferrajoli; Marylou Cardenas-Turanzas; Susan Lerner; Jeffrey L Jorgensen; Graciela M Nogueras-González; Gracy Zacharian; Xuelin Huang; Hagop Kantarjian; Naveen Garg; Andreas Rosenwald; Susan O'Brien
Journal:  Lancet Oncol       Date:  2014-08-20       Impact factor: 41.316

3.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

4.  Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

Authors:  Constantine S Tam; Susan O'Brien; William Wierda; Hagop Kantarjian; Sijin Wen; Kim-Anh Do; Deborah A Thomas; Jorge Cortes; Susan Lerner; Michael J Keating
Journal:  Blood       Date:  2008-04-14       Impact factor: 22.113

5.  Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

Authors:  Valentin Goede; Kirsten Fischer; Raymonde Busch; Anja Engelke; Barbara Eichhorst; Clemens M Wendtner; Tatiana Chagorova; Javier de la Serna; Marie-Sarah Dilhuydy; Thomas Illmer; Stephen Opat; Carolyn J Owen; Olga Samoylova; Karl-Anton Kreuzer; Stephan Stilgenbauer; Hartmut Döhner; Anton W Langerak; Matthias Ritgen; Michael Kneba; Elina Asikanius; Kathryn Humphrey; Michael Wenger; Michael Hallek
Journal:  N Engl J Med       Date:  2014-01-08       Impact factor: 91.245

6.  Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.

Authors:  Susan O'Brien; Richard R Furman; Steven E Coutre; Jeff P Sharman; Jan A Burger; Kristie A Blum; Barbara Grant; Donald A Richards; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Raquel Izumi; Ahmed Hamdy; Betty Y Chang; Thorsten Graef; Fong Clow; Joseph J Buggy; Danelle F James; John C Byrd
Journal:  Lancet Oncol       Date:  2013-12-10       Impact factor: 41.316

7.  Validation of the Cumulative Illness Rating Scale in a geriatric residential population.

Authors:  P A Parmelee; P D Thuras; I R Katz; M P Lawton
Journal:  J Am Geriatr Soc       Date:  1995-02       Impact factor: 5.562

8.  Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.

Authors:  Ekkehard Mössner; Peter Brünker; Samuel Moser; Ursula Püntener; Carla Schmidt; Sylvia Herter; Roger Grau; Christian Gerdes; Adam Nopora; Erwin van Puijenbroek; Claudia Ferrara; Peter Sondermann; Christiane Jäger; Pamela Strein; Georg Fertig; Thomas Friess; Christine Schüll; Sabine Bauer; Joseph Dal Porto; Christopher Del Nagro; Karim Dabbagh; Martin J S Dyer; Sibrand Poppema; Christian Klein; Pablo Umaña
Journal:  Blood       Date:  2010-03-01       Impact factor: 22.113

9.  Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.

Authors:  Sylvia Herter; Frank Herting; Olaf Mundigl; Inja Waldhauer; Tina Weinzierl; Tanja Fauti; Gunter Muth; Doris Ziegler-Landesberger; Erwin Van Puijenbroek; Sabine Lang; Minh Ngoc Duong; Lina Reslan; Christian A Gerdes; Thomas Friess; Ute Baer; Helmut Burtscher; Michael Weidner; Charles Dumontet; Pablo Umana; Gerhard Niederfellner; Marina Bacac; Christian Klein
Journal:  Mol Cancer Ther       Date:  2013-07-19       Impact factor: 6.261

10.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113
View more
  64 in total

1.  Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions.

Authors:  Ciara L Freeman; Franck Morschhauser; Laurie Sehn; Mark Dixon; Richard Houghton; Thierry Lamy; Günter Fingerle-Rowson; Elisabeth Wassner-Fritsch; John G Gribben; Michael Hallek; Gilles Salles; Guillaume Cartron
Journal:  Blood       Date:  2015-10-07       Impact factor: 22.113

Review 2.  Update on therapy of chronic immune-mediated neuropathies.

Authors:  Chiara Briani; Dario Cocito; Marta Campagnolo; Pietro Emiliano Doneddu; Eduardo Nobile-Orazio
Journal:  Neurol Sci       Date:  2021-01-16       Impact factor: 3.307

Review 3.  Relapsed CLL: sequencing, combinations, and novel agents.

Authors:  Jennifer R Brown
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 4.  Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia.

Authors:  Gilad Itchaki; Jennifer R Brown
Journal:  Ther Adv Hematol       Date:  2017-11-28

Review 5.  Targeted Therapy in Chronic Lymphocytic Leukemia (CLL).

Authors:  Erin M Pettijohn; Shuo Ma
Journal:  Curr Hematol Malig Rep       Date:  2017-02       Impact factor: 3.952

Review 6.  Initial treatment of CLL: integrating biology and functional status.

Authors:  Nitin Jain; Susan O'Brien
Journal:  Blood       Date:  2015-06-11       Impact factor: 22.113

Review 7.  The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars.

Authors:  Jennifer R Brown; Florence Cymbalista; Jeff Sharman; Ira Jacobs; Pilar Nava-Parada; Anthony Mato
Journal:  Oncologist       Date:  2017-12-06

Review 8.  The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia.

Authors:  Gilad Itchaki; Jennifer R Brown
Journal:  Ther Adv Hematol       Date:  2016-07-08

Review 9.  Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting.

Authors:  Spencer H Bachow; Nicole Lamanna
Journal:  Curr Hematol Malig Rep       Date:  2016-02       Impact factor: 3.952

Review 10.  Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective.

Authors:  Carolyn J Owen; Douglas A Stewart
Journal:  Ther Adv Hematol       Date:  2015-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.